Skip to main content
Signal8
Launch Terminal

CYTOKINETICS INC (CYTK)

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

NASDAQ:CYTKHealthcare
-0.51%$62.99
AH$63.15+0.25%vs close
Mkt Cap$8.76B
Float121.07M
O/S139.02M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Cytokinetics, Incorporated logoNASDAQ:CYTK$62.99-0.51%
Upcoming Catalysts
Phase Distribution
41 lead-sponsored trials·5 active·28 completed
Phase 19
Phase 1/21
Phase 218
Phase 2/32
Phase 311
(5 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

    Tirasemtiv, Placebo tablets

    Amyotrophic Lateral Sclerosis

    Enrollment
    744
    Start
    Sep 2015
    Primary Completion
    Mar 2017
    Completion
    Sep 2017
    NCT02496767
  • Phase 3
    Completed

    Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

    Omecamtiv Mecarbil, Placebo

    Heart Failure

    Enrollment
    8,256
    Start
    Jan 2017
    Primary Completion
    Sep 2020
    Completion
    Sep 2020
    NCT02929329
  • Phase 3
    Completed

    A Study for Patients Who Completed VITALITY-ALS (CY 4031)

    tirasemtiv

    Amyotrophic Lateral Sclerosis (ALS)

    Enrollment
    280
    Start
    Oct 2016
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT02936635
  • Phase 3
    Completed

    Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

    Omecamtiv Mecarbil, Placebo

    Heart Failure With Reduced Ejection Fraction

    Enrollment
    276
    Start
    Apr 2019
    Primary Completion
    Nov 2021
    Completion
    Jan 2022
    NCT03759392
  • Phase 3
    Withdrawn

    Omecamtiv Mecarbil Post-trial Access Study

    Omecamtiv mecarbil

    Chronic Heart Failure With Reduced Ejection Fraction

    Enrollment
    0
    Start
    Dec 2020est.
    Primary Completion
    Nov 2026est.
    Completion
    Nov 2026est.
    NCT04464525
  • Phase 3
    Terminated

    A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

    Reldesemtiv, Placebo

    Amyotrophic Lateral Sclerosis

    Enrollment
    489
    Start
    Aug 2021
    Primary Completion
    Jul 2023
    Completion
    Jul 2023
    NCT04944784
  • Phase 3
    Completed

    Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

    Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten

    Obstructive Hypertrophic Cardiomyopathy (oHCM)

    Enrollment
    282
    Start
    Feb 2022
    Primary Completion
    Nov 2023
    Completion
    Dec 2023
    NCT05186818
  • Phase 3
    Terminated

    A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

    Reldesemtiv

    Amyotrophic Lateral Sclerosis

    Enrollment
    71
    Start
    Aug 2022
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT05442775
  • Phase 3
    Completed

    Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

    Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten

    Obstructive Hypertrophic Cardiomyopathy (oHCM)

    Enrollment
    175
    Start
    Jun 2023
    Primary Completion
    Feb 2025
    Completion
    Mar 2025
    NCT05767346
  • Phase 3
    Active, not recruiting

    A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

    Aficamten, Placebo

    Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

    Enrollment
    500
    Start
    Aug 2023
    Primary Completion
    Aug 2026
    Completion
    Nov 2026est.
    NCT06081894
  • Phase 3
    Recruiting

    Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

    Omecamtiv Mecarbil (OM), Placebo

    Heart Failure, Heart Failure With Reduced Ejection Fraction

    Enrollment
    1,800
    Start
    Dec 2024
    Primary Completion
    Sep 2027est.
    Completion
    Dec 2027est.
    NCT06736574
  • Phase 2/3
    Enrolling by invitation

    Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

    Aficamten (5 - 20 mg)

    Symptomatic Hypertrophic Cardiomyopathy (HCM)

    Enrollment
    900
    Start
    May 2021
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2029est.
    NCT04848506
  • Phase 2/3
    Active, not recruiting

    A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

    Aficamten, Placebo

    Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Enrollment
    65
    Start
    May 2024
    Primary Completion
    Jan 2030est.
    Completion
    Jan 2030est.
    NCT06412666
  • Phase 2
    Completed

    A Study of CK-1827452 Infusion in Stable Heart Failure

    CK-1827452, CK-1827452

    Heart Failure

    Enrollment
    45
    Start
    Apr 2007
    Primary Completion
    Feb 2009
    Completion
    Feb 2009
    NCT00624442
  • Phase 2
    Completed

    PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

    CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg capsule

    Heart Failure, Myocardial Ischemia +1

    Enrollment
    94
    Start
    Apr 2008
    Primary Completion
    Nov 2008
    Completion
    Mar 2009
    NCT00682565
  • Phase 2
    Terminated

    Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

    CK-1827452, CK-1827452

    Heart Failure

    Enrollment
    2
    Start
    Sep 2008
    Primary Completion
    Nov 2008
    Completion
    Jul 2009
    NCT00748579
  • Phase 2
    Completed

    Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure

    CK-1827452, CK-1827452

    Heart Failure

    Enrollment
    35
    Start
    Apr 2009
    Primary Completion
    Oct 2009
    Completion
    Oct 2009
    NCT00941681
  • Phase 2
    Withdrawn

    Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

    Omecamtiv mecarbil

    Heart Failure

    Enrollment
    0
    Start
    Jul 2010
    Primary Completion
    May 2011
    Completion
    May 2011est.
    NCT01077167
  • Phase 2
    Completed

    A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    Placebo, 250 mg CK-2017357

    Amyotrophic Lateral Sclerosis

    Enrollment
    67
    Start
    Mar 2010
    Primary Completion
    Nov 2010
    Completion
    Nov 2010
    NCT01089010
  • Phase 2
    Completed

    A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

    Placebo, 375 mg CK-2017357

    Intermittent Claudication, Peripheral Artery Disease

    Enrollment
    61
    Start
    May 2010
    Primary Completion
    Mar 2011
    Completion
    Mar 2011
    NCT01131013
  • Phase 2
    Terminated

    Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

    Placebo, 250 mg CK-2017357

    Myasthenia Gravis

    Enrollment
    32
    Start
    Dec 2010
    Primary Completion
    Oct 2012
    Completion
    Oct 2012
    NCT01268280
  • Phase 2
    Completed

    Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

    Placebo, Omecamtiv mecarbil

    Heart Failure

    Enrollment
    614
    Start
    Apr 2011
    Primary Completion
    Apr 2013
    Completion
    Sep 2013
    NCT01300013
  • Phase 2
    Completed

    A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    Placebo (Part A), CK-2017357 (Part A)

    Amyotrophic Lateral Sclerosis

    Enrollment
    49
    Start
    Jun 2011
    Primary Completion
    Mar 2012
    Completion
    Mar 2012
    NCT01378676
  • Phase 2
    Completed

    Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    CK-2017357, Placebo

    Amyotrophic Lateral Sclerosis

    Enrollment
    27
    Start
    Nov 2011
    Primary Completion
    Mar 2012
    Completion
    Mar 2012
    NCT01486849
  • Phase 2
    Completed

    Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

    CK-2017357, Riluzole

    Amyotrophic Lateral Sclerosis

    Enrollment
    711
    Start
    Oct 2012
    Primary Completion
    Mar 2014
    Completion
    Mar 2014
    NCT01709149

1-25 of 41

Search ClinicalTrials.gov for “Cytokinetics”